1 Leinonen, M & Saikku, P (2002) Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2, 11–17.
2 Kannel, WB, Castelli, WP & Gordon, T (1979) Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham Study. Ann Intern Med 90, 85–91.
3 Castelli, WP (1988) Cholesterol and lipids in the risk of coronary artery disease – the Framingham Heart Study. Can J Cardiol 4, Suppl. A, 5A–10A.
4 Yang, CS & Landau, JM (2000) Effects of tea consumption on nutrition and health. J Nutr 130, 2409–2412.
5 Mukhtar, H & Ahmad, N (2000) Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 71, 1698S–1702S.
6 Zaveri, NT (2006) Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 78, 2073–2080.
7 Rice-Evans, CA, Miller, NJ & Paganga, G (1996) Structure–antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 20, 933–956.
8 Shankar, S, Ganapathy, S & Srivastava, RK (2007) Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci 12, 4881–4899.
9 Matsumoto, N, Ishigaki, F, Ishigaki, A, et al. (1993) Reduction of blood glucose levels by tea catechin. Biosci Biotechnol Biochem 57, 525–527.
10 Miura, Y, Chiba, T, Tomita, I, et al. (2001) Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J Nutr 131, 27–32.
11 Murase, T, Haramizu, S, Shimotoyodome, A, et al. (2005) Green tea extract improves endurance capacity and increases muscle lipid oxidation in mice. Am J Physiol Regul Integr Comp Physiol 288, R708–R715.
12 Murase, T, Nagasawa, A, Suzuki, J, et al. (2002) Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver. Int J Obes Relat Metab Disord 26, 1459–1464.
13 Imai, K & Nakachi, K (1995) Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. Br Med J 310, 693–696.
14 Kono, S, Shinchi, K, Wakabayashi, K, et al. (1996) Relation of green tea consumption to serum lipids and lipoproteins in Japanese men. J Epidemiol 6, 128–133.
15 Muramatsu, K, Fukuyo, M & Hara, Y (1986) Effect of green tea catechins on plasma cholesterol level in cholesterol-fed rats. J Nutr Sci Vitaminol 32, 613–622.
16 Matsuda, H, Chisaka, T, Kubomura, Y, et al. (1986) Effects of crude drugs on experimental hypercholesterolemia. I. Tea and its active principles. J Ethnopharmacol 17, 213–224.
17 Chisaka, T, Matsuda, H, Kubomura, Y, et al. (1988) The effect of crude drugs on experimental hypercholesteremia: mode of action of ( − )-epigallocatechin gallate in tea leaves. Chem Pharm Bull 36, 227–233.
18 Ando, T, Nishimura, T, Matsubayashi, A, et al. (1989) Effects of tea catechins on cholesterol absorption with exogenously hypercholesterolemic rat (ExHC-Ta). Bull Kanagawa Dent Coll 17, 21–23.
19 Yang, TT & Koo, MW (1997) Hypocholesterolemic effects of Chinese tea. Pharmacol Res 35, 505–512.
20 Chan, PT, Fong, WP, Cheung, YL, et al. (1999) Jasmine green tea epicatechins are hypolipidemic in hamsters (Mesocricetus auratus) fed a high fat diet. J Nutr 129, 1094–1101.
21 Yang, TT & Koo, MW (2000) Chinese green tea lowers cholesterol level through an increase in fecal lipid excretion. Life Sci 66, 411–423.
22 Bursill, CA & Roach, PD (2006) Modulation of cholesterol metabolism by the green tea polyphenol ( − )-epigallocatechin gallate in cultured human liver (HepG2) cells. J Agric Food Chem 54, 1621–1626.
23 Lee, MS, Park, JY, Freake, H, et al. (2008) Green tea catechin enhances cholesterol 7alpha-hydroxylase gene expression in HepG2 cells. Br J Nutr 99, 1182–1185.
24 Morikawa, K, Kondo, I, Kanamaru, Y, et al. (2007) A novel regulatory pathway for cholesterol degradation via lactostatin. Biochem Biophys Res Commun 352, 697–702.
25 Snedecor, GW & Cochran, WG (1967) Statistical Methods, 6th ed. Ames, IA: The Iowa State University Press (Japanese edition; Tokyo: Iwanami Publishers, Inc.).
26 Hayter, AJ (1984) A proof of the conjecture that the Tukey–Kramer multiple comparisons procedure is conservative. Ann Statist 12, 61–75.
27 Beglova, N & Blacklow, SC (2005) The LDL receptor: how acid pulls the trigger. Trends Biochem Sci 30, 309–317.
28 Sniderman, AD, Scantlebury, T & Cianflone, K (2001) Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135, 447–459.
29 Javitt, NB (1990) Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J 4, 161–168.
30 Izem, L, Rassart, E, Kamate, L, et al. (1998) Effect of reduced low-density lipoprotein receptor level on HepG2 cell cholesterol metabolism. Biochem J 329, 81–89.
31 Wilson, GM, Roberts, EA & Deeley, RG (1997) Modulation of LDL receptor mRNA stability by phorbol esters in human liver cell culture models. J Lipid Res 38, 437–446.
32 Mehta, KD, Radominska-Pandya, A, Kapoor, GS, et al. (2002) Critical role of diacylglycerol- and phospholipid-regulated protein kinase C epsilon in induction of low-density lipoprotein receptor transcription in response to depletion of cholesterol. Mol Cell Biol 22, 3783–3793.
33 Kamps, JA & van Berkel, TJ (1993) Regulation of low-density-lipoprotein receptors in the human hepatoma cell line Hep G2. Effect of phorbol 12-myristate 13-acetate and low-density lipoprotein. Eur J Biochem 213, 989–994.
34 Kumar, A, Chambers, TC, Cloud-Heflin, BA, et al. (1997) Phorbol ester-induced low density lipoprotein receptor gene expression in HepG2 cells involves protein kinase C-mediated p42/44 MAP kinase activation. J Lipid Res 38, 2240–2248.
35 Vargas, NB, Brewer, BY & Rogers, TB (2009) Protein kinase C activation stabilizes LDL receptor mRNA via the JNK pathway in HepG2 cells. J Lipid Res 50, 386–397.
36 Zhao, Y, Yu, L, Xu, S, et al. (2011) Down-regulation of connexin43 gap junction by serum deprivation in human endothelial cells was improved by ( − )-epigallocatechin gallate via ERK MAP kinase pathway. Biochem Biophys Res Commun 404, 217–222.
37 Takahashi, S, Sakai, J, Fujino, T, et al. (2004) The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor. J Atheroscler Thromb 11, 200–208.
38 Oliver, WR Jr, Shenk, JL, Snaith, MR, et al. (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 98, 5306–5311.
39 Sakakura, Y, Shimano, H, Sone, H, et al. (2001) Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. Biochem Biophys Res Commun 286, 176–183.
40 Brown, MS & Goldstein, JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331–340.
41 Murase, T, Misawa, K, Haramizu, S, et al. (2009) Catechin-induced activation of the LKB1/AMP-activated protein kinase pathway. Biochem Pharmacol 78, 78–84.
42 Chen, L, Lee, MJ, Li, H, et al. (1997) Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos 25, 1045–1050.
43 Nakagawa, K & Miyazawa, T (1997) Absorption and distribution of tea catechin, ( − )-epigallocatechin-3-gallate, in the rat. J Nutr Sci Vitaminol 43, 679–684.
44 Nagaoka, S, Kamuro, H, Oda, H, et al. (1991) Effects of polychlorinated biphenyls on cholesterol and ascorbic acid metabolism in primary cultured rat hepatocytes. Biochem Pharmacol 41, 1259–1261.
45 Soutar, AK & Naoumova, RP (2007) Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 4, 214–225.